Octreotide for recurrent intestinal bleeding due to ventricular assist device

Asian Cardiovasc Thorac Ann. 2014 Mar;22(3):350-2. doi: 10.1177/0218492312474902. Epub 2013 Aug 16.

Abstract

We report the case of a 64-year-old Jarvik 2000 recipient with a high risk of bleeding (anticoagulation treatment and acquired von Willebrand disease), who presented with intractable gastrointestinal hemorrhage due to severe gastric angiodysplasia. He was successfully treated with long-acting octreotide.

Keywords: Angiodysplasia; gastrointestinal hemorrhage; heart-assist devices; octreotide.

Publication types

  • Case Reports

MeSH terms

  • Angiodysplasia / diagnosis
  • Angiodysplasia / drug therapy*
  • Angiodysplasia / etiology
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Gastrointestinal Hemorrhage / diagnosis
  • Gastrointestinal Hemorrhage / drug therapy*
  • Gastrointestinal Hemorrhage / etiology
  • Heart Failure / diagnosis
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Heart-Assist Devices / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Octreotide / therapeutic use*
  • Prosthesis Design
  • Recurrence
  • Stomach Diseases / diagnosis
  • Stomach Diseases / drug therapy*
  • Stomach Diseases / etiology
  • Treatment Outcome
  • Ventricular Function, Left*
  • von Willebrand Diseases / etiology

Substances

  • Anticoagulants
  • Gastrointestinal Agents
  • Octreotide